BCL2L1 and acute myeloid leukemia: This study provides the first side-by-side comparison of selective and potent BH3-mimetics targeting the main antiapoptotic proteins MCL-1, BCL-2 or BCL-xL in a larger panel of AML primary samples and AML cell lines.